ONCT Oncternal Corp: Accounting Value per Share

Public company logo of Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics (ONCT) maintains a strong reputation for developing targeted antibodies against metastases, focusing on underserved segments of solid and hematologic tumor treatments. The book value per share reflects a trend of asset accumulation, with the 3.08 mark characterizing this parameter. The company specializes in combating rare cancers by blocking stem cell proteins to prevent relapses.

ONCT - Oncternal Therapeutics Inc Book Value of One Share over the range 07/04/2022 - 12/14/2024

Summary analytical data breakdowns for oncternal.com (ONCT)

- price and consensus price forecast:
Stock Price Oncternal|ONCT - Consensus Target
- market capitalization data:
Market Valuation Oncternal Therapeutics, Inc.|ONCT - Aggregate Business Value
- book capitalization data:
Book Value per Share Oncternal Therapeutics|ONCT - Book Value of Business|Market Capitalization to Book Value Ratio oncternal.com|ONCT - Company Assets
- debt and liquidity data:
Debt to Equity Oncternal Therapeutics|ONCT - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Oncternal Therapeutics, Inc.|ONCT - Company Cumulative Debt|Debt to Book Capitalization Ratio Oncternal Therapeutics, Inc.
Fundamental company valuation:ONCT Oncternal
Manufactured product of oncternal.com

For Oncternal Therapeutics (ONCT), whose success depends on clinical trials rather than economic cycles, net asset dynamics reflect the real value of capital. By analyzing the estimated BVPS, an investor can see the company's residual value per share after deducting all liabilities, which allows for an assessment of resource management efficiency amid the Fed's tight monetary policy.

Competitors of Oncternal Therapeutics (ONCT)

INCY: Book Value per Share|HUTCHMED Corp (HCM) - Accounting Value per Share|NUVB - Accounting Value per Share|dayonebio.com (DAWN) - Book Price of a Share|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CHRS (Coherus Biosciences) - Book Value per Share|CRBP: Net Asset Value per Share|Net Assets per Single Share cardiffoncology.com CRDF|BeyondSpring Inc (BYSI) - Accounting Value of a Share|BCAB (BioAtla Inc) - Book Value per Share|Book Value per Share LIXT|Net Assets per Single Share Citius Pharmaceuticals (CTXR)|Net Assets per Single Share Cellectar Biosciences Inc CLRB|Accounting Value per Share BioLineRx Corp|Can-Fite - Accounting Value of a Share|APRE (Aprea) - Net Assets per Single Share|KZIA: Net Asset Value per Share|Net Assets per Single Share silexion.com|NuCana (NCNA) - Equity per Share|Book Value per Share CMRX|Accounting Value per Share CYCC|G1 Therapeutics, Inc. - Net Assets per Single Share|Net Asset Value per Share KRON (kronosbio.com)|Net Assets per Single Share Kintara Therapeutics, Inc. KTRA|Portage Biotech Inc - Net Assets per Single Share